Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies
暂无分享,去创建一个
Andrew J. Maloney | Moo Sun Hong | R. Braatz | S. Manalis | S. Springs | A. Sinskey | P. Barone | Sha Sha | G. Katsikis | T. Nguyen | J. Wolfrum | Andrew J Maloney | Andreas Gimpel | Andreas L. Gimpel | Andreas L. Gimpel
[1] R. Puri,et al. Clinical Development of Gene Therapies: The First Three Decades and Counting , 2020, Molecular therapy. Methods & clinical development.
[2] Toshimitsu Tanaka,et al. Optimization of the quality by design approach for gene therapy products: a case study for adeno-associated viral vectors. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[3] J. Sheng,et al. Creation of a High-Yield AAV Vector Production Platform in Suspension Cells Using a Design-of-Experiment Approach , 2020, Molecular therapy. Methods & clinical development.
[4] P. Alves,et al. Holographic Imaging of Insect Cell Cultures: Online Non-Invasive Monitoring of Adeno-Associated Virus Production and Cell Concentration , 2020, Processes.
[5] S. DeVries,et al. Quantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes , 2020, bioRxiv.
[6] R. Samulski,et al. Engineering adeno-associated virus vectors for gene therapy , 2020, Nature Reviews Genetics.
[7] P. Kukura,et al. Single molecule mass photometry of nucleic acids , 2020, bioRxiv.
[8] Hongshan Li,et al. Rapid, Automated, At-Line AAV2 Virus Quantitation Advances Bioprocessing in Gene Therapy AAV2 Virus Binding and Standard Curve Generation AAV2 Virus Quantitation , 2020 .
[9] Weibin Chen,et al. Anion-Exchange Chromatography for Determining Empty and Full Capsid Contents in Adeno-Associated Virus , 2020 .
[10] Zhi-Yao He,et al. The approved gene therapy drugs worldwide: from 1998 to 2019. , 2019, Biotechnology advances.
[11] K. Müller,et al. Adeno-associated virus capsid protein expression in Escherichia coli and chemically defined capsid assembly , 2019, Scientific Reports.
[12] SubramanianSuriyasri,et al. Filling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy , 2019, Human Gene Therapy.
[13] Rui M. C. Portela,et al. Enabling PAT in insect cell bioprocesses: In situ monitoring of recombinant adeno‐associated virus production by fluorescence spectroscopy , 2019, Biotechnology and bioengineering.
[14] T. Linke,et al. Developing an Anion Exchange Chromatography Assay for Determining Empty and Full Capsid Contents in AAV6.2 , 2019, Molecular therapy. Methods & clinical development.
[15] D. Pimentel,et al. Production of adeno-associated virus vectors for in vitro and in vivo applications , 2019, Scientific Reports.
[16] Wei-Chiang Chen,et al. Analytical strategies for quantification of adeno-associated virus (AAV) empty capsids to support process development. , 2019, Human gene therapy methods.
[17] E. Uchida,et al. Two-Dimensional Droplet Digital PCR as a Tool for Titration and Integrity Evaluation of Recombinant Adeno-Associated Viral Vectors , 2019, Human gene therapy methods.
[18] Hyunmi Lee,et al. Accurate Quantification and Characterization of Adeno-Associated Viral Vectors , 2019, Front. Microbiol..
[19] Mario Schelhaas,et al. Virus-like particle size and molecular weight/mass determination applying gas-phase electrophoresis (native nES GEMMA) , 2019, Analytical and Bioanalytical Chemistry.
[20] M. Lock,et al. Stability of the adeno-associated virus 8 reference standard material , 2019, Gene Therapy.
[21] J. Schrag,et al. Achieving High-Yield Production of Functional AAV5 Gene Delivery Vectors via Fedbatch in an Insect Cell-One Baculovirus System , 2019, Molecular therapy. Methods & clinical development.
[22] Daniel R. Blessing,et al. Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells , 2018, Molecular therapy. Methods & clinical development.
[23] L. Vandenberghe,et al. Quantitative and Digital Droplet-Based AAV Genome Titration. , 2019, Methods in molecular biology.
[24] A. Tamaoka,et al. Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9 , 2018, Molecular therapy. Methods & clinical development.
[25] E. Ayuso,et al. Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls , 2018, Molecular therapy. Methods & clinical development.
[26] Daniel C. Cole,et al. Quantitative mass imaging of single biological macromolecules , 2018, Science.
[27] C. Heiner,et al. Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras , 2018, Molecular therapy. Methods & clinical development.
[28] E. Ayuso,et al. Pharmacology of Recombinant Adeno-associated Virus Production , 2018, Molecular therapy. Methods & clinical development.
[29] Seng H. Cheng,et al. Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes , 2017, Molecular therapy. Methods & clinical development.
[30] J Lizbeth Reyes Zamora,et al. Flow virometry as a tool to study viruses. , 2017, Methods.
[31] U. Gottschalk,et al. New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins , 2018 .
[32] Determination of adenovirus concentration using Biacore T200 , 2018 .
[33] Marco Jenzsch,et al. Trends in Process Analytical Technology: Present State in Bioprocessing. , 2018, Advances in biochemical engineering/biotechnology.
[34] A. Shukla,et al. High-Throughput Process Development for Biopharmaceuticals. , 2018, Advances in biochemical engineering/biotechnology.
[35] S. Crosson,et al. Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] Kristen A. Severson,et al. Opportunities and challenges of real‐time release testing in biopharmaceutical manufacturing , 2017, Biotechnology and bioengineering.
[37] Rejane L Petersen. Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development , 2017, Biosensors.
[38] Manuel J T Carrondo,et al. Universal label-free in-process quantification of influenza virus-like particles. , 2017, Biotechnology journal.
[39] H. Büning,et al. Improving the Quality of Adeno-Associated Viral Vector Preparations: The Challenge of Product-Related Impurities , 2017 .
[40] H. Germain,et al. Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data , 2017, Scientific Reports.
[41] B. Cogné,et al. Accurate Identification and Quantification of DNA Species by Next-Generation Sequencing in Adeno-Associated Viral Vectors Produced in Insect Cells. , 2017, Human gene therapy methods.
[42] R. Kotin,et al. Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines. , 2017, Human gene therapy.
[43] A. Kamen,et al. Manufacturing of recombinant adeno‐associated viruses using mammalian expression platforms , 2017, Biotechnology journal.
[44] Aleksandar Sebesta,et al. Label-Free Single-Molecule Imaging with Numerical-Aperture-Shaped Interferometric Scattering Microscopy , 2016, ACS photonics.
[45] G. Massolini,et al. Advances on Size Exclusion Chromatography and Applications on the Analysis of Protein Biopharmaceuticals and Protein Aggregates: A Mini Review , 2017, Chromatographia.
[46] T. Weber,et al. Production and Characterization of Vectors Based on the Cardiotropic AAV Serotype 9. , 2017, Methods in molecular biology.
[47] H. Katus,et al. Protocol for Efficient Generation and Characterization of Adeno-Associated Viral Vectors. , 2017, Human gene therapy methods.
[48] Nadja Alt,et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. , 2016, Biologicals : journal of the International Association of Biological Standardization.
[49] Helen Wu,et al. Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. , 2016, Analytical biochemistry.
[50] M. Jarrold,et al. Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. , 2016, Analytical chemistry.
[51] J. Grieger,et al. Manufacturing of recombinant adeno-associated viral vectors for clinical trials , 2016, Molecular therapy. Methods & clinical development.
[52] J. Grieger,et al. Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[53] Linshu Liu,et al. High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction. , 2016, Human gene therapy.
[54] D. Saunders,et al. Influenza vaccine titer determination using biolayer interferometry (BLI) , 2015, BMC Proceedings.
[55] Yongchang Cao,et al. Rapid quantitation of porcine epidemic diarrhea virus (PEDV) by Virus Counter. , 2015, Journal of virological methods.
[56] Seng H. Cheng,et al. Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors. , 2015, Human gene therapy methods.
[57] R. Thorpe,et al. Systematic Comparison and Validation of Quantitative Real-Time PCR Methods for the Quantitation of Adeno-Associated Viral Products , 2015, Human gene therapy methods.
[58] Randal J. Schoepp,et al. Evaluation of ViroCyt® Virus Counter for Rapid Filovirus Quantitation , 2015, Viruses.
[59] D. Gavin. FDA statement regarding the use of adeno-associated virus reference standard materials. , 2015, Human gene therapy methods.
[60] PiedraJose,et al. Development of a Rapid, Robust, and Universal PicoGreen-Based Method to Titer Adeno-Associated Vectors , 2015 .
[61] S. Berkowitz,et al. Size-Exclusion Chromatograph (SEC) in Biopharmaceutical Process Development , 2015 .
[62] Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products , 2015 .
[63] L. Zentilin,et al. Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. , 2014, Human gene therapy.
[64] Christopher J Roberts,et al. Therapeutic protein aggregation: mechanisms, design, and control. , 2014, Trends in biotechnology.
[65] G. K. Raju,et al. Understanding Pharmaceutical Quality by Design , 2014, The AAPS Journal.
[66] M. R. Delgado Alvira,et al. Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. , 2014, Human gene therapy methods.
[67] J. F. Wright,et al. Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment , 2014, Biomedicines.
[68] Nathan Cermak,et al. Weighing nanoparticles in solution at the attogram scale , 2014, Proceedings of the National Academy of Sciences.
[69] W. Xiao,et al. A reliable and feasible qPCR strategy for titrating AAV vectors , 2013, Medical science monitor basic research.
[70] J. Carpenter,et al. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. , 2013, Journal of pharmaceutical sciences.
[71] S. Harvey,et al. Biophysical and Ultrastructural Characterization of Adeno-Associated Virus Capsid Uncoating and Genome Release , 2012, Journal of Virology.
[72] C. Mueller,et al. Production and Discovery of Novel Recombinant Adeno‐Associated Viral Vectors , 2012, Current protocols in microbiology.
[73] Arun Srivastava,et al. Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. , 2012, Human gene therapy methods.
[74] K. Rapti,et al. Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels. , 2012, Human gene therapy methods.
[75] L. Pease,et al. Physical analysis of virus particles using electrospray differential mobility analysis. , 2012, Trends in biotechnology.
[76] P. Fagone,et al. Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. , 2012, Human gene therapy methods.
[77] M. R. Delgado Alvira,et al. Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. , 2012, Human gene therapy methods.
[78] Jeff Mellen,et al. High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.
[79] K. Brorson,et al. Evaluation of electrospray differential mobility analysis for virus particle analysis: Potential applications for biomanufacturing , 2011, Journal of Virological Methods.
[80] P. Fagone,et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. , 2011, Human gene therapy.
[81] J. F. Wright,et al. Vector characterization methods for quality control testing of recombinant adeno-associated viruses. , 2011, Methods in molecular biology.
[82] M. Audit,et al. rAAV vector product characterization and stability studies. , 2011, Methods in molecular biology.
[83] E. Ayuso,et al. Production, purification and characterization of adeno-associated vectors. , 2010, Current gene therapy.
[84] Patrick Garidel,et al. Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development , 2010, Pharmaceutical Research.
[85] Terence R Flotte,et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. , 2010, Human gene therapy.
[86] W. Jiskoot,et al. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. , 2010, Journal of pharmaceutical sciences.
[87] John P. Gabrielson,et al. Precision of protein aggregation measurements by sedimentation velocity analytical ultracentrifugation in biopharmaceutical applications. , 2010, Analytical biochemistry.
[88] J. Philo,et al. A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.
[89] J. F. Wright,et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[90] Carl-Fredrik Mandenius,et al. Bioprocess optimization using design‐of‐experiments methodology , 2008, Biotechnology progress.
[91] J. F. Wright,et al. Manufacturing and characterizing AAV-based vectors for use in clinical studies , 2008, Gene Therapy.
[92] A. Pekar,et al. Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: practical considerations that affect precision and accuracy. , 2007, Analytical biochemistry.
[93] J. Kleinschmidt,et al. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. , 2007, Journal of virological methods.
[94] H. Mizukami,et al. Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[95] J. F. Wright,et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[96] M. S. Chapman,et al. Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. , 2004, Journal of virological methods.
[97] Alan McClelland,et al. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[98] Thomas Scheper,et al. Flow cytometry in biotechnology , 2001, Applied Microbiology and Biotechnology.
[99] D. Grimm,et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2 , 1999, Gene Therapy.
[100] P Hajdú,et al. [Analytical methods I]. , 1975, Arzneimittel-Forschung.